Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Price:
25.97
CNY
-0.23%
Market Cap:
¥10.8B
Income Statement
Earnings Waterfall
Liaoning Chengda Biotechnology Co Ltd
Liaoning Chengda Biotechnology Co Ltd
Income Statement
Liaoning Chengda Biotechnology Co Ltd
Liaoning Chengda Biotechnology Co Ltd
Currency: CNY
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
0
|
|
| Revenue |
1 859
N/A
|
1 797
-3%
|
1 713
-5%
|
1 815
+6%
|
1 802
-1%
|
1 805
+0%
|
1 789
-1%
|
1 750
-2%
|
1 761
+1%
|
1 759
0%
|
1 718
-2%
|
1 676
-2%
|
1 670
0%
|
1 502
-10%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
(200)
|
(204)
|
(212)
|
(243)
|
(272)
|
(301)
|
(308)
|
(343)
|
(326)
|
(330)
|
(335)
|
(319)
|
(332)
|
(304)
|
|
| Gross Profit |
1 659
N/A
|
1 593
-4%
|
1 501
-6%
|
1 572
+5%
|
1 530
-3%
|
1 504
-2%
|
1 481
-2%
|
1 408
-5%
|
1 435
+2%
|
1 429
0%
|
1 384
-3%
|
1 357
-2%
|
1 338
-1%
|
1 198
-10%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(831)
|
(845)
|
(864)
|
(818)
|
(808)
|
(800)
|
(860)
|
(885)
|
(1 002)
|
(1 052)
|
(1 013)
|
(946)
|
(991)
|
(963)
|
|
| Selling, General & Administrative |
(605)
|
(611)
|
(642)
|
(573)
|
(608)
|
(625)
|
(654)
|
(623)
|
(680)
|
(678)
|
(653)
|
(631)
|
(668)
|
(660)
|
|
| Research & Development |
(208)
|
(241)
|
(229)
|
(162)
|
(209)
|
(187)
|
(188)
|
(171)
|
(235)
|
(279)
|
(288)
|
(206)
|
(276)
|
(255)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(102)
|
0
|
0
|
0
|
(109)
|
0
|
0
|
0
|
(136)
|
0
|
0
|
|
| Other Operating Expenses |
(17)
|
6
|
7
|
18
|
9
|
13
|
(18)
|
18
|
(87)
|
(96)
|
(72)
|
26
|
(47)
|
(48)
|
|
| Operating Income |
828
N/A
|
748
-10%
|
637
-15%
|
753
+18%
|
723
-4%
|
705
-2%
|
621
-12%
|
523
-16%
|
433
-17%
|
377
-13%
|
370
-2%
|
411
+11%
|
347
-16%
|
235
-32%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
50
|
74
|
128
|
86
|
89
|
81
|
77
|
106
|
99
|
71
|
59
|
36
|
31
|
43
|
|
| Non-Reccuring Items |
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(51)
|
3
|
3
|
3
|
(42)
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
|
| Total Other Income |
8
|
(1)
|
2
|
(0)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(3)
|
(2)
|
(1)
|
(3)
|
(2)
|
|
| Pre-Tax Income |
887
N/A
|
821
-7%
|
767
-7%
|
838
+9%
|
810
-3%
|
785
-3%
|
697
-11%
|
576
-17%
|
534
-7%
|
448
-16%
|
429
-4%
|
403
-6%
|
375
-7%
|
277
-26%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
(124)
|
(123)
|
(114)
|
(124)
|
(120)
|
(118)
|
(108)
|
(110)
|
(113)
|
(96)
|
(97)
|
(60)
|
(42)
|
(32)
|
|
| Income from Continuing Operations |
763
|
698
|
653
|
714
|
690
|
667
|
588
|
466
|
420
|
353
|
332
|
343
|
334
|
245
|
|
| Net Income (Common) |
763
N/A
|
698
-9%
|
653
-6%
|
714
+9%
|
690
-3%
|
667
-3%
|
588
-12%
|
466
-21%
|
420
-10%
|
353
-16%
|
332
-6%
|
343
+3%
|
334
-3%
|
245
-27%
|
|
| EPS (Diluted) |
1.83
N/A
|
1.67
-9%
|
1.56
-7%
|
1.71
+10%
|
1.66
-3%
|
1.6
-4%
|
1.41
-12%
|
1.12
-21%
|
1.01
-10%
|
0.84
-17%
|
0.8
-5%
|
0.83
+4%
|
0.83
N/A
|
0.56
-33%
|
|
Switch to:
Switch to:
See Also
Discover More
